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In this section, the anti-infectives considered are the antibiotics, including anti-tuberculotic 
drugs, the anti-viral drugs, and the anti-fungal drugs. 
 
18.1. Antibiotics 
 18.1.1 Introduction to bacteria 
Bacteria are unicellular (one cell) micro-organisms that do not have a nucleus.  The DNA 
information of bacteria is stored in a single chromosome.  If the bacteria are spherical, they 
are called cocci, whereas if they are rod shaped, they are called bacilli.  Each bacterium 
grows to a fixed size and then divides by binary fission to give two bacteria.  Most bacteria 
are rendered harmless by the immune system, and this is one of the main functions of the 
immune system.  The most common fatal bacterial infections are respiratory infections (e.g. 
pneumonia) and tuberculosis (TB). 
 
Bacteria are separated into two groups by a stain developed by a person called Gram.  These 
groups are Gram positive and Gram negative bacteria.  Gram-positive microbials have a 
simple cell wall which is 50% peptidoglycan and 40-45% acidic polymer with a negative 
charge.  Gram-negative microbials have a much more complex cell wall.  Gram-positive 
microbials are much easier to treat than gram-negative microbials as they allow cell 
penetration by positively charged agents.  Also, because of the petidoglycan structure of 
Gram-positive microbials, inhibitors of cell wall/peptidoglycan synthesis are more effective 
against Gram-positive than Gram-negative microbials. 
 
Clinically significant Gram-positive bacteria include Staphylococci,which are associated with 
acne, and Streptococci, which can cause sore throat, middle ear infections, and bacterial 
pneumonia.  Examples of pathogenic (disease-causing) Gram-negative bacteria include 
Neisseria meningitidis (meningitis), Neisseria gonorrhoea (gonorrhea), and Salmonella 
enteria (gastrointestinal upsets).  Haemophilus influenzae, which causes bacterial meningitis 
and ear infections in children and pneumonia in adults, and is also Gram-negative. 
 
 18.1.2 Introduction to antibiotics 
The term chemotherapy is used to describe the use of drugs to treat infections caused by 
invading cells and therefore cover the anti-infective drugs and anti-cancer drugs.  However, 
many people think of chemotherapy only in the treatment of cancer. The term selective 
toxicity is mainly used to describe the anti-microbials.  Selective toxicity relates to a drug 
having toxicity to the invading microbial without toxicity to the host (e.g. the human). 
 
Selective toxicity relies on differences in bacterial (prokaryote cells) and human/mammalian 
cells (eukaryote cells).  Selective toxicity can be achieved by drugs attacking processes or 
pathways which are present in the microbial cell, but not the mammalian cell.  For example, 
both prokaryote and eukaryote cells have cell membranes, but only the prokaryote cells have 
cell walls.  Bacterial cell walls are often made of peptidoglycan, and the bacterial cell wall is 
a site at which antibacterial agents can attack.  Eukaryote cells have their genetic material 
contained within a nucleus, whereas prokaryote cells only have a single chromosome 
containing all their genetic material.  Some of the structures and processed involved in  
bacterial DNA synthesis, RNA synthesis and protein synthesis are different from those in 
the mammalian cells and can be targets for antibacterial agents.  For example, the ribosomes 
are the place where protein synthesis takes place, and there are structural differences between 
the ribosomes in eukaryote and prokaryote cells.  Thus, the bacterial ribosomes are a site at 
which antibacterial agents can attack.  This chapter considers antibiotics that attack at these 
different sites. 
 
Antibiotics can be classed as bactericidal or bacteriostatic.  Antibiotics that are bactericidal 
cause the death of the bacteria.  To be bactericidal, antibiotics usually interfere with cell wall 
synthesis or disrupt the cell membrane.  Antibiotics that are bacteriostatic prevent the 
growth or division of bacteria.  Once the growth of the bacteria has been arrested, it is hoped 
that the body’s own immune system will takes care of the remaining bacteria by killing them.  
To be bacteriostatic, drugs usually interfere with protein or nucleic acid synthesis in the 
bacteria. 
 
Antimicrobials can be narrow or broad spectrum.  Narrow spectrum anti-microbials are only 
effective against a small number of microbials.  Broad spectrum anti-microbials are anti-
microbials that are effective against a wider range of microbial species. 
 
One topic about antibiotics that is commonly in the news is the emergence of drug-resistant 
organisms, which is largely blamed on the overuse and misuse of antibiotics.  There are two 
main types of resistance.  The first is due to chromosomal mutations in the bacteria, so that 
they take on a form that is no longer susceptible to the antibiotics.  The best know example of 
this is Methicillin-resistant Staphylococcus Aureus (MRSA), which is resistant to the drug 
methicillin, which is one of the penicillins.  MRSA causes severe infections, and is a problem 
in many hospitals.  The second type of resistance is due to the induction of enzymes or 
transporters/carriers in the microbe.  For example, microbials that have been treated 
successfully with the β-lactam penicillins in the past, have now induced their levels of the 
enzyme β-lactamase.   The induced β-lactamases increase the breakdown of the penicillins, 
making them less effective. 
 
18.1.3 Inhibitors of bacterial cell wall synthesis 
The cell wall of bacteria is a semi-rigid structure.  The cell wall not only determines the shape 
of the organism, but also contains the cell contents necessary for survival.  Anything that 
weakens the structure of the cell wall can cause the bacterium to break apart which will kill it.  
These agents are usually bacteriocidal.  Figure 18.1 outlines the steps involved in the 
synthesis of the bacterial cell wall and where antibacterial agents can act to inhibit this 
process. 
 
 
Figure 18.1 Steps involved in the synthesis of the bacterial cell wall (Copyright Monash 
University, Elizabeth Davis) 
 
 
  18.1.3.1 β-Lactams 
Probably, the best known examples of antibiotics are the penicillins.  The penicillins are from 
the β-lactams group of inhibitors of bacterial cell wall synthesis.  The β-lactams are a group 
of chemically related agents that also includes the cephalosporins and the carbapenams. All 
of the β-lactams inhibit the synthesis of the bacterial cell wall.  In particular, the β-lactams 
inhibit enzymes (transpeptidases) involved in cross-linking the peptidoglycans.Their action 
weakens the cell wall so that the bacteria lyses (ruptures).  The β-lactams are bactericidal, 
which means they kill susceptible bacteria.  Unfortunately, resistance to the β-lactams has 
developed.  This resistance is due to induction of β-lactamases in microbials, and these β-
lactamases can breakdown some β-lactams, which makes them ineffective. The spectrum of 
activity of the different β-lactams is determined by the transpeptidase enzymes they target 
and their susceptibility to breakdown by the β-lactamases.   
 
Penicillins are considered the drugs of choice for many infections.  The first penicillins were 
the naturally occurring penicillins such as benzylpenicillin (also known as penicillin G).  
Benzylpenicillin is bactericidal and has a narrow spectrum of activity.  Benzylpenicillin is 
more effective against Gram-positive than Gram-negative microbials.  The main 
disadvantage of benzylpenicillin is that it is destroyed by the acid in the stomach, and cannot 
be used orally.  Benzylpenicillin is used intravenously or intramuscularly in serious 
infections.  For instance, benzylpenicillin is used to treat bacterial endocarditis (which is 
inflammation of inner heart with streptococci), meningitis, pneumonia, and syphilis. 
 
Further development of the penicillins was undertaken to provide an orally active compound.  
An example of an orally active penicillin is amoxycillin.  Amoxycillin is semisynthetic and 
has a moderate spectrum of activity.  However, amoxycillin is broken down by β-lactamases.  
Thus, microbials that have induction of β-lactamases, are not susceptible to amoxicillin.   
 
One way to overcome this is to use amoxycillin in combination with the irreversible β-
lactamase inhibitor clavulanic acid.  The clavulanic acid inhibits the β-lactamase, so that the 
β-lactamase cannot destroy the amoxycillin, and amoxycillin remains available to inhibit the 
synthesis of the bacterial cell wall.  Clavulanic acid therefore increases the spectrum of 
activity of amoxycillin.  The combination of amoxycillin and clavulanic acid is known as co-
amoxiclav.   
 
Amoxycillin alone is used orally or intravenously in the treatment of a number of bacterial 
infections including chronic bronchitis, pneumonia, ear infections, sinusitis and gonococcal 
infection (“the clap”). Amoxycillin in combination with clavulanic acid is used in ear and 
sinus infections unresponsive to amoxycillin alone i.e. when the amoxycillin is broken down 
by the β-lactamases.  The combination treatment is also used orally in severe pneumonia, and 
epididymo-orchitis (infection of epididymis/testis). 
 
Another approach when microbes have developed resistance to amoxycillin is to use a 
penicillin that is resistant to β-lactamases.  Flucloxacillin is not susceptible to β-lactamases, 
and this is a major advantage over amoxycillin.  Flucloxacillin is active against the β-
lactamase producing Staphylcocci responsible for a number of skin infections (e.g. boils, 
carbuncles, mastitis, and infected scabies) and are used in the treatment of these infections.  
However, a disadvantage of flucloxacillin is that it is narrow spectrum, and is only effective 
against a small spectrum of microbes.  Flucloxacillin is also used in the treatment, of 
infections in bones and joints. 
 
One problem with the penicillins is that 10% of people are allergic to penicillins.  As 
penicillin allergy can be very severe on a second exposure, this should be avoided.  People 
who are allergic to penicillin have to take alternative antibiotics.  
 
The second group of β-lactams are the cephalosporins.  The cephalosporins are broad 
spectrum and bacteriocidal.  Like the penicillins, the cephalosporins weaken the bacterial cell 
wall. However, the cephalosporins are rarely first choice antibiotic therapy as they commonly 
cause gastrointestinal adverse effects.  They are often used to treat infections in patients 
allergic to penicillins. 
 
Cephalexin was one of the first cephalosporins synthesised, and is known as a first 
generation cephalosporin.  Cephalexin is one of the few cephalosporins active after oral 
administration.  Cephalexin is a moderate spectrum antibacterial and is more effective against 
Gram-positive than Gram-negative bacteria, Despite this, cephalexin is used to treat 
infections of the urinary tract caused by Gram-negative bacteria.  The main use of cephalexin 
is in the treatment of Straphylococcal and Streptococcal infections in subjects allergic to 
penicillin. 
 
From the structure of the first generation of cephalosporins, such as cephalexin, the scientists 
tried to change the structure to improve effectiveness against Gram-negative bacteria.  An 
example of a second generation cephalosporin is cefuroxime.  Cefuroxime is active after oral 
or intravenous administration.  Cefuroxime is a very important antibiotic as it is more 
effective against Gram-negative than Gram-positive bacteria, which provides us with an 
antibiotic that can be used in serious Gram-negative bacterial infections including those 
caused by Haemophillus influenza (e.g. hospital and community acquired pneumonia), 
meningitis and septicaemia. 
 
Further cephalosporins were developed to exploit this ability to inhibit Gram-negative 
bacteria.  An example of a third generation cephalosporin is cefotaxime.  Cefotaxime is not 
active after oral administration, which is a disadvantage.  It is used intravenously.  Like 
cefuroxime, cefotaxime is more effective against Gram-negative than Gram-positive bacteria.  
Cefotaxime is used intravenously in the treatment of severe infections such as pneumonia, 
orbital cellulitis (eye infection), bacterial meningitis and septicaemia.  
 
Other -lactams antibacterials have been developed to be resistant to breakdown by the -
lactamases.  These are the carbapenams and monobactams.  The carbapenams are considered 
to have the broadest spectrum of all antibacterials.  Imipenem is a carbapenams and is 
effective against Gram-positive and Gram-negative organisms.  It was originally resistant to 
all β-lactamases, which made it a very effective antibiotic.  However, this resistance has not 
lasted, and new β-lactamases have been induced by the bacteria to breakdown imipenem and 
reduce its effectiveness.  Imipenem is used in the treatment of life-threatening infections, 
particularly hospital-acquired infections, when other antibacterials are not considered 
appropriate. 
  18.1.4.2 Glycopeptides   
An important approach to preventing microbes developing resistance to antibiotics, is to limit 
the use of antibiotics, so that the microbes do not have the opportunity to develop resistance.  
Thus, when new antibiotics are developed there is initially an attempt to limit their use, so 
that they remain useful in serious infections.  This occurred with the glycopeptide, 
vancomycin.  Like the β-lactams, glycopeptides inhibit the synthesis of the bacterial cell 
wall.  The glycopeptides do this by inhibiting the enzymes involved in building the 
peptidoglycan structure (transglycosidases). International guidelines have been developed to 
restrict the use of vancomycin to try to prevent the development of vancomycin resistant 
bacteria.  Vancomycin is reserved mainly for treatment of life-threatening infections with 
Methicillin-Resistant Staphylococcus Aureus (MRSA).  As the name implies MRSA is 
resistant to the penicillins, including methicillin.  Staphylococci are the commonest cause of 
hospital bloodstream infections.  MRSA spreads quickly among elderly and seriously ill 
patients.  Unfortunately, the effectiveness of vancomycin against MRSA is declining.   
 
 18.1.5 Inhibitors of bacterial protein synthesis 
Within the cell, ribosomes are the sites of protein synthesis.  The ribosomes and protein 
synthesis in bacteria and humans are different.  In particular, the structure of the bacterial 
ribosome is different from that of the mammalian ribosome. Thus, it is possible to inhibit 
bacterial protein synthesis without altering the protein synthesis of the human, and this gives 
selective toxicity against the microbes over the humans.  In the process of bacterial protein 
synthesis, the first step involves the transfer (t) RNA with an attached amino acid binding to 
the ribosome (Figure 18.2).   
 
Figure 18.2 Steps involved in bacterial protein synthesis 
 
The second step in bacterial protein synthesis is that the tRNA with the amino acid attached 
forms base pairs with the ribosome.  The third step is transpeptidation, when the amino 
acid chain is transferred onto incoming tRNA-amino acid, with the addition of the protein to 
the amino acid, so the protein has one more amino acid on it.  The fourth step is 
translocation, when the ribosome moves along the mRNA and releases the free tRNA 
allowing next tRNA-amino acid to bind.  Finally, there is separation of the protein from the 
ribosome. 
 
Every step in this bacterial protein synthesis at the ribosome is a step we can interfere with 
using drugs.  For instance, the binding of amino acid carrying tRNA- to the ribosome is 
inhibited by the group of antibiotics known as the tetracyclines.  The second step, the 
formation of base pairs, is inhibited by the aminoglycosides.   The third step, the 
transpeptidation, is inhibited by chloramphenicol, and the fourth step, the translocation of 
the ribosome alone the mRNA, is inhibited by the macrolides.  Each of these antibiotics is 
discussed below. 
 
18.1.4.1 Tetracyclines 
Probably the best known example of a tetracycline that is used clinically is doxycycline.  The 
tetracyclines, such as doxycycline inhibit the binding of the transfer (t)RNA, which has the 
amino acid attached, to the bacterial ribosomes, and hence inhibits the synthesis of proteins in 
the bacteria. The tetracyclines are considered bacteriostatic not bactericidal.  Thus, they halt 
the multiplication of the bacteria, rather than killing the bacteria.  The tetracyclines are broad 
spectrum i.e. stop the replication of many bacteria.  The tetracyclines are used orally in the 
treatment of respiratory tract infections. They are also used in the treatment of acne.  
However, doxycycline can cause gastrointestinal upsets (nausea, vomiting and diarrhoea).  
Furthermore, the tetracycyclines combine with calcium and can cause discolouration of teeth 
and decrease bone growth.  For this reason, they are not given to young children or pregnant 
women.  Another problem with the tetracyclines is the development of widespread resistance.   
 
The resistance to the tetracyclines is due to the induction of transporters in the bacteria 
membrane that remove the tetracyclines from the bacterium.  When the tetracyclines are 
being transported out of the bacteria, there will be reduced concentrations of the tetracyclines 
in bacterium cell.  As the effectiveness of the tetracycline depends on the concentration at the 
target site, when they are transported out of the cell, the concentration in the cell will drop, 
and there will be reduced effectiveness. 
 
  18.1.4.2 Aminoglycosides 
The aminoglycosides bind to the bacterial ribosome and interfere with the binding of the 
tRNA.  This leads to the wrong amino acid being added to the peptide.    Gentamicin and 
neomycin are examples of aminoglycoside antibiotics.   
 
The entry of gentamicin into bacterium is by oxygen-dependent active transport.  Thus, 
gentamicin is much more effective against aerobic (oxygen-requiring) than anaerobic (not 
requiring oxygen) bacteria.  Gentamicin is more effective against aerobic Gram-negative than 
Gram-positive bacteria.  This is a positive, as Gram-negative bacteria are usually more 
difficult to treat than Gram-positive bacteria.  Gentamicin is used in the treatment of serious 
Gram-negative bacterial infections (e.g. septicaemia), and in cystic fibrosis and 
bronchiectasis, where there is an increased risk of infection in damaged lungs.  Resistance to 
gentamicin is increasing, and this resistance is due to induction of metabolising enzymes in 
the bacteria, that metabolise and inactive the gentamicin. 
 
Gentamicin is highly polar (ionized) and, consequently, it is not absorbed from 
gastrointestinal tract.  Gentamicin is used intraventously (iv) or intramuscularly (im) for 
systemic infections.  Gentamicin is inhaled when it is used in respiratory infections associated 
with cystic fibrosis or bronchiectasis.  Gentamicin is predominantly eliminated from the 
kidney, and consequently it is necessary to reduce the dose in patients with renal impairment 
to prevent the plasma concentration rising to toxic levels.  Gentamicin is reserved for serious 
infections that are not easily treated with other antibiotics because it cannot be used orally, 
and because it can cause serious toxicity.  The serious toxicity with gentamicin includes 
irreversible damage to the ear (ototoxicity) leading to the loss of balance, or even deafness, 
and damage to the kidney (nephrotoxicity) which fortunately is reversible.  
 
Neomycin is used as a broad spectrum aminoglycoside antibiotic.  Neomycin is used 
topically for the treatment of infections of the skin and mucous membranes e.g. impetigo 
(‘school sores’) and boils.  Neomycin is also used in some anti-acne lotions, to treat acne that 
is associated with a bacterial infection. 
 
  18.1.4.3 Chloramphenicol 
The transpeptidation process in bacterial protein synthesis involves an amino acid being 
added onto a growing peptide chain.  This step is inhibited by chloramphenicol.  
Chloramphenicol is suitable for oral or intravenous use.  It is bacteriostatic against most 
bacteria but does kill Haemophilus influenza.  It can also be applied topically, e.g. in ear 
drops, to treat ear infections.  Resistance to chloramphenicol is due to presence of 
chloramphenicol acetyltransferase produced by resistant strains of Gram-positive and Gram-
negative bacteria, and the chloramphenicol acetyltransferase inactivates the chloramphenicol, 
which obviously reduces the effectiveness of chloramphenicol.   
 
Chloramphenicol is not a very well tolerated drug.  It can cause depression of bone marrow 
leading to pancytopenia (decrease in all elements of blood), which is a serious adverse effect.  
The use of chloramphenicol is limited, as its benefit must outweigh its risk, for it to be used.  
Its use it usually in infections which have failed to respond to other antibiotics or cannot be 
used.  For instance, chloramphenicol is used in meningitis when penicillin cannot be used.  
The adverse effects of chloramphenicol are not an issue when it is used topically. 
 
  18.1.4.4 Macrolides 
Erythromycin is an example of a macrolide.  The macrolides inhibit the translocation step in 
bacterial protein synthesis (i.e. the separation of the protein, after another amino acid has 
been added).  Erythromycin is bateriostatic and broad spectrum.  It is effective against Gram-
positive and against a few Gram-negative bacteria.  Erythromycin is used as an alternative to 
penicillin and cephalosporins in people who are allergic to these antibiotics.  Erythromycin is 
also used in respiratory tract infections. 
 
Erythromycin is suitable for oral or intravenous use.  Erythromycin is metabolised by the 
liver enzyme CYP 3A4.  Consequently, drugs that inhibit CYP 3A4 (grapefruit juice, 
ketoconazole) increase the levels of erythromycin, and this can lead to toxic effects of 
erythromycin.  The toxic effects of erythromycin include a prolongation of QT interval, 
which indicates a slowing of ventricular repolarisation and can lead to cardiac arrhythmia.   
 
18.1.4.5 Lincosamides 
An example of a lincosamide is clindamycin.  Clindamycin has two mechanisms of actions; 
it inhibits both bacterial transpeptidation and translocation.  Clindamycin is active against 
Gram-positive cocci, including many penicillin-resistant staphylococci and many anaerobic 
bacteria.  One of the main uses of clindamycin is, oral or topically, for the treatment of any 
bacterial infection associated with acne. 
 
18.1.4.6  Oxalazidones 
The oxalazidones are a new chemical class of antibiotics.  Linezolid is an example of an 
oxalazidone.  Oxalazidones bind to the 50S ribosomal unit of the bacteria, to prevent it 
forming the 70S complex, and without this ribosome complex there is no bacterial protein 
synthesis.  Linezolid is reserved for the treatment of drug-resistant Gram-positive organisms 
e.g. vancomycin-resistant enterococci.  Linezolid is also used as an alternative to vancomycin 
for the treatment of MRSA (Methicillin-Resistant Staphylococci Aureus). 
  18.1.5 Inhibitors of DNA synthesis 
An example of an antibiotic that inhibits the DNA synthesis in bacteria is trimethoprim.  
Trimethoprim is classified as a folate inhibitor.  Trimethoprim inhibits the enzyme 
dihydrofolate reductase, by competing with folic acid for the enzyme.  Dihydrofolate 
reductase is necessary to promote the incorporation of folic acid into DNA.  When this 
enzyme is inhibited with trimethoprim, there is reduced production of bacterial DNA, which 
stops the bacteria from undergoing binary fission.  Trimethoprim is bacteriostatic.  Thus, it 
halts the division of existing bacterial, but does not kill the existing bacteria.  Hopefully, the 
immune system will deal with the remaining bacteria.  Trimethoprim is used orally, mainly to 
treat urinary tract infections. 
 
18.2. Anti-tuberculotic drugs 
 
In this section, there is a very brief introduction to tuberculosis, and the first-line treatment of 
it. 
 
 18.2.1 Introduction 
Tuberculosis, commonly known as TB, is caused by Mycobacteria tuberculosis, which is a 
very slow-growing bacterium.  Tuberculosis mainly affects the lungs, and infection is spread 
by inhalation of infectious aerosols.  In the developing world, 7 million new cases of TB are 
reported annually, and 3 million people die of this disease annually.  In Australia, the TB 
notification rates are 5/100,000, which means that 5 people out of every 100,000 have TB.  
TB is a disease of low social status and overcrowding, with the overcrowding promoting the 
spread of the TB.  In Australia, the people who are most likely to have TB are the refugees 
and migrants from countries with a high-incidence of TB,  people with alcohol or drug 
dependence, the homeless, HIV-(human immunodeficiency virus)-infected people, and 
indigenous people. 
 
Unfortunately, there is no single drug that is effective in the treatment of TB, partly because it 
is so slowly growing, and partly because resistance has developed to the drugs which used to 
be used to treat TB.  One of the other problems with treating mycobacterial infections is that 
the mycobacteria have a more complex cell wall structure, which is less permeable to many 
chemicals.  The mycobacteria are, therefore, resistant to many of the commonly used 
antibacterial agents.  The first-line treatment for TB is a combination of ethambutol, 
isoniazid, rifampicin and pyrazinamide for two months.  This is followed by isoniazid 
and rifampicin for a further minimum of four months.  Isoniazid and ethambutol are 
bactericidal/bacteriostatic and effective against the actively dividing Mycobacteria.  
Rifampicin and pyrazinamide have a sterilising (killing) action against the Mycobacteria 
when they are present but not dividing (i.e. dormant cells). 
 
 18.2.2 Isoniazid 
Isoniazid has a similar structure to nicotinic acid, and because of this it causes inhibition of 
nicotinamide adenine dinucleotide (NAD) synthesis.  Without NAD, there is inhibition of 
synthesis of mycolic acids, which are constituents of mycobacterial cell wall.  As a result of 
preventing the synthesis of the mycobacterial cell wall, isoniazid is bactericidal in actively 
dividing cells but bacteriostatic in resting cells.  Unfortunately, with continued use, resistance 
develops to isoniazid, and it loses effectiveness. 
 
Unfortunately, isoniazid also has effects on the host.  Isoniazid interferes with Vitamin B6 
(pyridoxime) metabolism, which makes the vitamin ineffective.  Vitamin B6 is required to 
maintain the integrity of peripheral nerves.  By interfering with the Vitamin B6 metabolism, 
isoniazid causes peripheral neuropathy.  This serious adverse effect of isoniazid can be 
avoided by supplementation with Vitamin B6 tablets to avoid peripheral neuropathy.  
Isoniazid in metabolised by acetylation to hepatotoxic metabolite.  There is a polymorphism 
of the acetylating enzyme and people can be either slow or fast acetylators.  The slow 
acetylators will have higher plasma levels of isoniazid and will be at an increased risk of 
peripheral neuropathy but at decreased risk of hepatotoxicity compared to fast acetylators.  In 
contrast, the fast acetylators have higher levels of the hepatotoxic metabolite (and the 
resulting toxicity).   The fast acetylators will have lower plasma levels of isoniazid.   
 
 18.2.3 Ethambutol 
Ethambutol is only active against Mycobacteria, not other bacteria.  Ethambutol is 
bacteriostatic, not bacteriocidal.  The mechanism of action of ethambutol that underlies this 
bacteriostatic effect is unclear. 
 
The most serious adverse effect with ethambutol is optic neuritis (inflammation of the optic 
nerve).  This neuritis may lead to blindness.  Fortunately the neuritis is usually reversed by 
stopping the treatment with ethambutol.  Ethambutol, also impairs the renal clearance of uric 
acid, and this can lead to hyperuricaemia and gout. 
 
 18.2.4 Rifampicin 
Rifampicin is one of the most important drugs in the treatment of tuberculosis.  Rifampicin 
acts to inhibit RNA synthesis in the Mycobacterium.  Importantly, this makes rifampicin 
bactericidal and effective against dormant cells.  As the most difficult thing to overcome in 
TB is the slow growth and presence of dormant cells, this makes rifampicin a very useful 
drug.  Rifampicin is the most important drug in the sterilising phase of treatment, the second 
phase of TB treatment, where the objective is to kill the dormant bacteria 
 
Rifampicin has few serious adverse effects.  One problem with rifampicin is that it induces 
liver enzymes, particularly CYP450 enzymes involved in drug metabolism.  This can lead to 
a decrease in the levels, and therefore the effectiveness of these drugs (e.g. oral 
contraceptives). 
 
The combination of isoniazid and rifampicin is very useful as it gives both bactericidal and 
sterilising effects. 
 
 18.2.5 Pyrazinamide 
The mechanism of action of pyrazinamide is probably similar to isoniazid, but not identical 
as pyrazinamide is able to kill dormant cells i.e. it has a sterilising agent.  Pyrazinamide, 
shares with isoniazid, the ability to cause hepatotoxicity.  Hepatotoxicity is common with 
high doses of pyrazinamide.  Consequently, pyrazinamide has to be used in low doses to 
avoid toxicity.  Using low doses reduces the effectiveness, and this is why pyrazinamide is 
used in combination with other drugs in TB.   
 
18.3. Anti-viral drugs 
This section is a brief introduction to viruses, and only considers the treatment of 3 specific 
viruses.  The 3 viruses considered are a DNA virus (herpesvirus), a RNA virus (influenza), 
and a retrovirus (HIV/AIDs). 
 18.3.1 Introduction to viruses 
Viruses are small (20-30 nm) infective agents that require a host cell (e.g. human cells) to 
replicate.  When a virus is outside of the host, it is known as a virion.   A virion is either a 
segment of RNA or DNA enclosed in a protein coat, which is called the capsid.   The capsid 
containing the nucleic acid (RNA or DNA) is called the nucleocapsid.  Viruses may also have 
an outer lipoprotein envelope.  Also, viruses may contain some enzymes required for 
replication in the host cell.  The actual structure varies between different types of viruses. 
 
There are 3 types of viruses; DNA viruses, RNA viruses, and retroviruses.  Examples of 
DNA viruses include herpesviruses, which can manifest itself as chickenpox, shingles, cold 
sores, or glandular fever.  Other common examples of DNA viruses are the adenoviruses 
which can cause sore throat, and conjunctivitis.  DNA viruses enter the host cell nucleus, and 
then they use the host cell RNA polymerase for transcription of their own DNA to viral RNA 
(Figure 18.3).  This is followed by translation and viral protein synthesis. 
 
Figure 18.3 Initial action of viruses (Copyright QUT, Sheila Doggrell) 
DNA v and RNAv are viral DNA and RNA respectively 
 
The RNA viruses include the viruses responsible for influenza and German measles, as well 
as the paramyxoviruses (cause measles, mumps) and picornaviruses (cause colds, meningitis, 
poliomyelitis).  The RNA of the RNA viruses is translated by the host enzyme systems to 
form the protein required for the synthesis of new virions (Figure 18.3).  
 
The best known example of a retrovirus is human immunodeficiency virus (HIV). HIV 
underlies acquired immunodeficiency syndrome (AIDS), which gives the person an increased 
susceptibility to infections and cancer.  
 
Retroviruses contain RNA as their genetic material, but in order for viral replication to occur, 
DNA must first be synthesised from the RNA template.  This step involves a viral specific 
enzyme reverse transcriptase enzyme (virus RNA-dependent DNA polymerase), which 
makes a DNA copy of the viral RNA (Figure 18.3).  Then, the DNA copy becomes part of 
host genome, known as provirus.  The provirus DNA is transcripted and mRNA translated by 
the host to make new virus particles.  
 
The chemotherapy of viral infections is dependent on the identification of viral specific 
proteins that can be selective targets for antiviral drugs.  While such targets have been 
identified, these are usually specific for a particular virus and therefore broad spectrum 
antiviral drugs are not available.  For this reason, the drugs are often classified according to 
the virus they act against rather than their mechanism of action. Furthermore, all of the 
currently used antiviral drugs are virustatic.  They are only active against the actively 
replicating cell and interfere with the spread of the infection.  As they do not kill any dormant 
forms of the virus, the dormant form of the virus may become active long after the initial 
infection (e.g. the herpes simplex virus is responsible for shingles long after an initial 
infection of chickenpox).   
 
There are a number of ways (targets) antiviral drugs can inhibit the virus.  These include 
inhibiting the attachment to and entry into the host cell of the virus, inhibition of the release 
of viral DNA/RNA and inhibition of the replication of viral DNA/RNA.  Alternative ways 
antiviral drugs can inhibit the action of viruses is to inhibit the assembly of new viral particles 
or the release of viral particles from the infected cell 
 
18.3.2 Drugs used to treat the herpesvirus 
The main drug used to treat the DNA virus, herpesvirus is aciclovir.  Aciclovir is a prodrug.  
It is converted by viral enzymes to aciclovir triphosphate, which inhibits viral DNA 
polymerase.  Thus, aciclovir acts by inhibiting the replication of viral DNA.  As it needs the 
viral enzyme to be converted to the active form, the selective toxicity of aciclovir is due to it 
being selectively ‘activated” in infected cells.   
 
Aciclovir is very good against herpes simplex (which causes cold sores, conjunctivitis, 
mouth ulcers, genital infections, encephalitis).  Herpes simplex is more susceptible to 
aciclovir than other herpesviruses such as varicella zoster (which causes chickenpox, 
shingles). 
 
Aciclovir can be used orally, but only has about a 20% bioavailability.  Aciclovir can also be 
used intravenously or topically.  Fortunately, the unwanted effects with aciclovir are minimal, 
espscially when it is used topically (eg for cold sores). 
 
18.3.3 Drugs used to treat the flu 
Viruses responsible for human flu (orthomyxoviruses) areRNA viruses (mainly 
influenzavirus A subtypes).  They cause symptoms similar to a cold.  However there are 
additional symptoms.  With the flu, the fever is greater than with a cold.  Also myalgia and 
prostration are symptoms of the flu not observed with a cold.  Infection is spread via the 
respiratory system. 
 
Each year in Australia, flu vaccines are developed against the influenza viruses that were 
most prevalent in the previous northern hemisphere winter.  The vaccine prevents the viral 
infection. 
 
Swine flu is also caused by an influenzavirus A subtype.  The symptoms of swine flu in 
humans are similar to the common human flu.  However, as it is a new virus, there is no 
natural immunity to swine flu.  It takes a minimum of 6 months to develop a vaccine to a new 
type of flu. 
 
Following replication and assembly of viral components, each virus particle exits the host 
cell, but remains attached until a viral specific enzyme (neuraminidase) releases it.   The 
neuraminidase inhibitors prevent this release, and are used to treat the flu.  Obviously, if the 
virus cannot leave the host cell, the further cell infection will be prevented.  Zanamivir 
(Relenza) and oseltamivir (Tamiflu) are examples of neuraminidase inhibitors.  Zanamivir 
was developed in Australia by a company (Biota) associated with Monash University.  
Zanamivir is administered as an aerosol, but for maximum benefit, must be taken within 48 
hours of the onset of the flu symptoms.  Oseltamivir is taken orally, also, as soon after the 
onset of flu symptoms, as possible. 
 
Both zanamivir and oseltamivir give some relief of the symptoms of the flu, as well as 
shortening the time the symptoms last..  Neuraminidase inhibitors (mainly oseltamivir) were 
stockpiled as a treatment for bird flu.  Fortunately the bird flu epidemic never happened.  
Neuraminidase inhibitors are probably effective in the swine flu, but this has not been fully 
evaluated. 
 
18.3.4 Drugs used to treat HIV/AIDS 
There are two main classes of drug used to treat infections with the retrovirus HIV.  These are 
the reverse transcriptase inhibitors and the protease inhibitors.  The reverse transcriptase 
inhibitors can be nucleoside analogs or non-nucleoside analogs.    
 
Because of the potential for resistance to develop to the available anti-retroviral drugs, the 
current guidelines are that combination treatment is always used.  One such combination is 
known as HAART or Highly Active Anti-Retroviral Therapy.  The HAART combination is 
two of the nucleoside reverse transcriptase inhibitors with EITHER a non-nucleoside 
transcriptase inhibitors OR one or two protease inhibitors.  Drugs that inhibit the fusion (and 
therefore entry) of the HIV with the host cells  are used when resistance develops to the other 
drugs.  All of the currently HIV drugs cause adverse effects that can make it likely that 
patients will not want to take them.  This means that often the treatment regimes are changed 
and developed for the individual patient to minimise the adverse effects and increase the 
likelihood that they will take them appropriately.     
 
The first drug developed for the treatment of HIV was AZT, which is also known as 
azidothymidine and zidovudine.  Zidovudine is a nucleoside reverse transcriptase 
inhibitor.  These drugs prevent the synthesis of the provirus DNA from the viral RNA (see 
Section 18.3.1).  Nucleosides analogs are phosphorylated by host cells to give triphosphate 
substrates which are then incorporated into the DNA chain by reverse transcriptase 
action.Zidovudine is an analog of the nucleoside thymidine, and substitutes for thymidine in 
this process.  Thus zidovudine competes with the endogenous nucleosides for the reverse 
transcriptase, and, once incorporated into the DNA chain, leads to the termination of the 
formation of the provirus DNA.  
 
Zidovudine is active after oral administration.  One of the main disadvantages with 
zidovudine is that it has short half-life, which means that it has to be administered every 4 
hours to be effective.  In addition, , zidovudine is only selective, not specific, for the reverse 
transcriptase.  The host mitochondrial γ-DNA polymerase is also inhibited by zidovudine, 
and this may underlie some of the side effects observed during zidovudine treatment.  In the 
treatment of HIV/AIDS, zidovudine has been shown to prolong life.  However, resistance 
develops to zidovudine, and this means it not effective alone, and has to be used in 
combination with other drugs.   
 
There are some serious adverse effects with zidovudine, probably because it can substitute for 
thymidine in many actions in the body.  Zidovudine causes bone marrow suppression leading 
to a decreased production of red blood cells (anaemia) and of the neutrophil white blood cells 
(neutropenia).  Blood transfusions may be required to overcome both of these.  Alternatively 
if anaemia is the main problem, this can be overcome by stimulating erythropoiesis (red 
blood cell formation) with epoetin (EPO).    Zidovudine can also cause headache, which can 
be controlled with paracetamol.  
 
Zidovudine and another nucleoside reverse transcriptase inhibitor are one part of the HAART 
treatment, and the other part is either a non-nucleoside reverse transcriptase inhibitor such as 
nevirapine or a protease inhibitor, such as ritonavir. 
 
Nevirapine binds to retroviral reverse transcriptase and denatures it.  Thus, nevirapine, like 
zidovudine, prevents the formation of the provirus DNA and the HIV replication.  Nevirapine 
differs from zidovudine in that it does not need to be converted to an active triphosphate in 
order to have its action.  Nevirapine is active after oral administration.  It induces its own 
metabolism.  Thus, with ongoing use it is necessary to increase the doses of nevirapine to 
maintain therapeutic plasma concentrations.  Nevirapine is contraindicated in subjects with 
impaired liver function, as it can worsen the liver function.  Importantly, in addition to being 
useful in HIV infection, nevirapine is also useful in preventing mother-to-baby transmission 
of the HIV.  Thus, nevirapine should be given to pregnant women to stop them from infecting 
their foetus. 
 
An example of a protease inhibitor is ritonavir.  The translation of the provirus RNA by the 
host ribosomes leads to the production of polypeptides.  These polypeptides are then acted on 
by viral proteases to give the structural proteins and active enzymes for the new virion.  By 
inhibiting the viral proteases, ritonavir inhibits this process i.e. the replication of the virus. 
New viral particles are released, but they are not infective. 
 
Ritonavir is active after oral administration.  One major adverse effect with ritonavir is 
hyperglycemia.  Thus, the subject with HIV treated with ritonavir can develop new diabetes, 
or if they are already diabetic, have a worsening of diabetes.  Another serious adverse effect 
with ritonavir is that it causes hypertriglyceridemia and hypercholesterolemia, and thus the 
subject may have to be treated with lipid lowering drugs to prevent cardiovascular disease. 
 
There are numerous drug interactions involving ritonavir as it inhibits the CYP enzymes 
(CYP3A) to increase levels of other drugs.  For example, ritonavir increases the levels of 
amiodarone, amlodipine, buprenorphine etc, and these levels may reach toxic levels.  
Ritonavir may also be used in combination with other protease inhibitors to inhibit the CYP 
enzymes and reduce the metabolism of these drugs.  In this way, it acts as a “pharmacokinetic 
booster”. 
 
When the resistance to HAART is such that the HIV continues to progress, other drugs have 
to be used.  The main one of these is enfuvirtide, which inhibits the fusion of the HIV with 
the host cell.  Normally the virus binds to the host cell, and then enters the host cell.  
Enfuvirtide inhibits the binding. 
 
Enfuvirtide is administered subcutaneously.  Enfuvirtide is used in HIV infection when other 
antiretrovirals have failed to halt the HIV.  It is common to get injection site reactions with 
enfuvirtide.  Treatment with enfuvirtide is associated with an increased risk of bacterial 
pneumonia. 
 
 18.4 Antifungal drugs 
  
18.4.1 Introduction to Fungi 
The word fungi means mushroom, and mushrooms were one of the first fungi characterised.  
Fungi are eukaryotic (they have a nucleus) and are harder to kill than prokaryotic bacteria 
(which do not have a nucleus).  Common examples of fungi are moulds and yeasts.  Fungi are 
symbiotic, which means they live in close association with a host, and are parasitic.  Fungal 
infections are known as mycoses.  Examples of mycoses include tinea (Athlete’s foot, 
Jockstrap itch, nails), Candida albicans (Thrush), Meningitis (which can be fungal or 
bacterial) and pulmonary aspergillosis (serious for bone marrow recipients, people with 
asthma or cystic fibrosis). 
 
 18.4.2 Antifungal drugs  
The fungal cell membrane is made up of ergosterol, which differs from the phospholipid 
plasma membrane of mammalian cells.  Thus, drugs that interfere with ergosterol will affect 
the fungal cell membrane, but not have effects in humans e.g. adverse effects.  Amphotericin 
is a mixture of anti-fungal substances derived from the bacteria, Streptomyces.  Amphotericin 
binds to ergosterol to create pores in the fungi cell membrane (Figure 18.4), and this leads to 
the death of the fungus i.e. is fungicidal. 
 
Amphotericin is poorly absorbed after oral administration, and is not used orally.  
Amphotericin is used either topically or intravenously.  One common adverse effect with 
amphotericin is renal toxicity, which occurs in 80% of people who are treated with it.  
Amphotericin also causes hypokalemia in a quarter of the people treated with it, and this 
hypokalemia may require treatment with potassium supplements.  Because of its serious 
adverse effects, amphotericin is not used in minor fungal infections.  Rather amphotericin is 
used in serious fungal infections e.g. treatment of fungal meningitis, pulmonary aspergillosis.  
Amphotericin lozenges have been developed to treat oral thrush. As there is little systemic 
absorption from these, there is little risk of adverse effects.   
 
Another anti-fungal drug that is mainly used for serious fungal infections is caspofungin.  
Caspofungin inhibits the synthesis of 1,3-β-glycan, a glucose polymer required for synthesis 
of fungal cell membrane.  It is used intravenously.  There are many common adverse effects 
with caspofungin (fever, nausea, vomiting, diarrhea), which limits its use to serious fungal 
infections such as invasive thrush and aspergillosis.  In aspergillosis, the first choice drug is 
an azole, and caspofungin is second choice. 
 
The azoles, such as fluconazole inhibit the enzyme lanosine demethylase (Figure 18.4), 
which is important in the conversion of lanosterol to ergosterol, the final step in the synthesis 
of ergosterol.  
 
Figure 18.4 Site of action of some antifungal drugs (Copyright QUT, Sheila Doggrell) 
 
Fluconazole is active after oral administration or after intravenous administration.  High 
concentrations of fluconazole get into the cerebral spinal fluid, and therefore reach the brain. 
For this reason, it is the drug of choice for the treatment of fungal meningitis.  Fluconazole is 
fungistatic, which means it stops the growth of the fungi, but does not kill them (i.e. it is not 
fungicidal).   The unwanted effects of fluconazole are mild.  The main problem when using 
fluconazole is that it inhibits the enzyme CYP3A4 (which is the CYP metabolising enzyme 
for many drugs).  Inhibition of CYP3A4 with fluconazole leads to increased levels of 
lignocaine, neviparine etc.  Fluconazole is used in the treatment of thrush and tinea.   
 
Terbinafine is the anti-fungal drug that is commonly used for the treatment of fungal 
infections of the nails, which is a common fungal infection.  Terbinafine inhibits the enzyme 
squalene epoxidase, which is involved in the conversion of squalene to lanosterol, in the early 
part of synthesis of fungal cell membranes (Figure 18.4).  Terbinafine is active after oral or 
topical administration.  Terbinafine is highly lipophilic, and is rapidly absorbed and taken up 
by nails and adipose tissue.  Terbinafine is very effective for fungal infections of nails. 
  
Griseofulvin interferes with fungal microtubules.  It is fungistatic.  It is reserved for when 
oral, long-term use is needed.  For instance, griseofulvin is used in tinea of head, skin, nails, 
groin, and feet, which is unresponsive to agents that are topically administered. 
 
